← All trials
NCT06042192
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 18, 2023
- Primary completion
- Oct 31, 2023
- Completion date
- Oct 31, 2023
- First posted
- Sep 18, 2023
- Last posted
- Sep 18, 2023
- Enrollment
- 80
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Teikoku Seiyaku Co., Ltd.Lead sponsor
- ClinSearch, LLCCollaborator
- CRM Biometrics GmbHCollaborator
- SocraMetrics GmbHCollaborator
- SocraTec R&D GmbHCollaborator
- Teikoku Seiyaku Co., Ltd.Study chair
- Teikoku Seiyaku Co., Ltd.Official
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.